Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @EUplatinum
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EUplatinum
-
February 2020 Issue Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer https://buff.ly/2SckGGe pic.twitter.com/XtCJ3KOSAI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort
#ProstateCancer https://buff.ly/2UmerCu pic.twitter.com/RxOxz6RDAX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Climbing over the Barriers of Current Imaging Technology in Urology https://buff.ly/2oEyQVF pic.twitter.com/vg3HdbDe7o
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition
#VisualAbstract https://buff.ly/36gxf8Q pic.twitter.com/HXLzDcAssH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
February 2020 Issue The Complex and Nuanced Care for Early-stage Testicular Cancer: Lessons from the European Association of Urology and American Urological Association Testis Cancer Guidelines
@Uroweb@AdityaBagrodia@drphil_urology https://buff.ly/2BUIbvz pic.twitter.com/cfuuY89spD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
February 2020 Issue: Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials: https://buff.ly/2S3JIqU Editorial:https://buff.ly/2rFZjTS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
February 2020 Issue: Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort https://buff.ly/3aPZfDk pic.twitter.com/zX2ErwWD3y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Platinum Editorial from Marko Babjuk: Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? https://buff.ly/2GCdlud pic.twitter.com/tm8J77Zzme
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Platinum Editorial from
@tompowles1 Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer https://www.europeanurology.com/article/S0302-2838(20)30047-6/fulltext …pic.twitter.com/9kblkydY2C
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
@apccc19@Silke_Gillessen@AOmlin@onco_uroloog@AlbertoBossial@Prof_IanD@mattsydes@ChrisSweens1 https://www.europeanurology.com/article/S0302-2838(20)30048-8/fulltext …#apccc19#prostatecancerpic.twitter.com/gYBRE5nSnV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
February 2020 Issue: Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial https://buff.ly/2Gsz1ce pic.twitter.com/iCvg5kXFoc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR) https://buff.ly/30RZcCz Editorial from
@Tom_Marcelissen and@kevinradem https://buff.ly/2pt8KWj pic.twitter.com/o9yG9ARk2w
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management
@Uroweb@JulieADarraugh@MariaJRibal@bjartell https://www.europeanurology.com/article/S0302-2838(20)30046-4/fulltext …pic.twitter.com/exmqnhtFaq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
@AndreaNecchi@F_Montorsi@u_capitanio#VisualAbstract https://buff.ly/2MeCxKh pic.twitter.com/eEcdRit3EH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study: https://buff.ly/2RnWaCC Editorial from
@aherlema : https://buff.ly/36vHyXA pic.twitter.com/Z54NQwRlhC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Platinum Editorial from Andre Luis Abreu: The Pillars for Sustained Growth of Magnetic Resonance Imaging Pathway for Prostate Cancer Diagnosis: Quality, Reproducibility, Accessibility, Cost Effectiveness, and Training https://buff.ly/36l6XSD pic.twitter.com/Qet4iUGwvU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations
@SamWashUro@aherlema@dr_coops@UCSFUrology https://www.europeanurology.com/article/S0302-2838(20)30045-2/fulltext …pic.twitter.com/H9jtWqbcNG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Words of Wisdom from Steven C. Campbell, Yun-Lin Ye, Zhiling Zhang, Joseph Zabell
@CleClinicUro Re: Impact of Acute Kidney Injury and its Duration on Long-term Renal Function after Partial Nephrectomy https://buff.ly/36FwDL2 pic.twitter.com/id2i1uB6ja
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort
@Uroweb@myESMO https://buff.ly/35gpfUJ pic.twitter.com/IVkGY4oArg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
February 2020 Issue: Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in CRPC: https://buff.ly/36gMgqS Editorial: https://buff.ly/33rZ3FR pic.twitter.com/9HIwR0YiP5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.